Alumis Inc.
ALMS
Rangering i aksjer
#10208
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aksjekurs
$6.38
Markedsverdi
$825.15M
Endring (1 dag)
4.17%
Endring (1 år)
180.84%
Land
US
Handel Alumis Inc. (ALMS)
Kategori
Healthcare
EPS for Alumis Inc. (ALMS)
EPS per March 2025 TTM: $-2.70
Ifølge de siste økonomiske rapportene og aksjekursen til Alumis Inc. er selskapets nåværende EPS (TTM) $-2.70. Ved slutten av 2023 hadde selskapet en EPS på $-5.43, en økning sammenlignet med EPS-en i 2022 som var $-0.70.
EPS-historikk for Alumis Inc. fra 2021 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
